Effect of oxytocin treatment on explant size, plasma and peritoneal levels of MCP-1, VEGF, TNF-α and histopathological parameters in a rat endometriosis model

other OA: closed public-domain-us
View on PubMed View at publisher
AI-generated summary by claude@2026-07, 2026-07-09

Oxytocin treatment in a rat endometriosis model reduced explant size, lowered inflammatory markers and VEGF, and increased apoptosis compared to controls.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

OBJECTIVE: To determine the effects of oxytocin (OT) on surgically induced endometriosis in a rat model. STUDY DESIGN: Twelve female Sprague-Dawley rats were included. After the implantation and establishment of autologous endometrium onto the abdominal wall peritoneum, the rats were randomly divided into two groups, treated with intramuscular oxytocin (OT group, 160μgkg/day, n=6) or isotonic NaCl solution (control group, 1mLkg/day, n=6) for 28 days. To evaluate the therapeutic effects of OT, the explant volumes were calculated and the levels of vascular endothelial growth factor (VEGF), monocyte chemotactic protein-1, and TNF-α were measured in plasma and peritoneal fluid. Endometriotic explants were examined histologically by semiquantitative analysis. RESULTS: After treatment, the mean endometriotic explant volume was decreased in the OT group (p=0.016). The histopathological score and VEGF immunoexpression of endometriotic explants were significantly lower in the OT group (p=0.007) than in controls (p=0.000). Inflammatory cytokine levels in plasma and peritoneal fluid were considerably decreased in the OT group. Moreover, TUNEL immunohistochemistry clearly demonstrated more apoptotic changes in the mononuclear cells of the OT group compared with controls. CONCLUSION: We suggest that oxytocin might be considered as a potential candidate therapeutic agent for endometriosis.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Chemokine CCL2 Endometriosis Oxytocin Tumor Necrosis Factor-alpha Vascular Endothelial Growth Factor A Animals Ascitic Fluid Ascitic Fluid Chemokine CCL2 Disease Models, Animal Drug Evaluation, Preclinical Endometriosis Endometriosis Endometriosis Female Oxytocin Rats Rats, Sprague-Dawley Tumor Necrosis Factor-alpha Vascular Endothelial Growth Factor A

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-08-07T06:07:27.085738+00:00
pubmed
last seen: 2026-05-13T22:18:40.923139+00:00
unpaywall
last seen: 2026-05-14T19:30:52.867331+00:00
License: public-domain-us · commercial use OK · attribution required
Courtesy of the U.S. National Library of Medicine